Journal of the National Cancer Institute Advance Access originally published online on December 25, 2007
JNCI Journal of the National Cancer Institute 2008 100(1):7-10; doi:10.1093/jnci/djm300
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
NEWS |
Recent Conference Addresses Research Integrity on Global Scale
| The first 150 words of the full text of this article appear below. |
The name Jon Sudbø is one that many in the cancer community will not soon forget. In early 2006, Sudbø admitted to fabricating patient data used in a study of nonsteroidal anti-inflammatory drugs and oral cancer risk published in The Lancet. Sudbø's institution, the Norwegian Radium Hospital, promptly appointed a special commission to investigate all his research from the previous decade. The commission found evidence of falsified and fabricated data dating back to Sudbø's Ph.D. project (J Natl Cancer Inst 2006;98:374–6).
The findings prompted the Norwegian government to formally put into place national research ethics committees tasked with proactive, preventive education on research integrity. The government also established a national office chaired by a judge to investigate cases of alleged scientific misconduct, and new legislation on ethics and integrity in research went into effect in July of this year.
The Sudbø case has parallels all over the world:
Defining Integrity
Dealing With Misconduct
International Action
Spelling Out the Problem: Integrity and Misconduct
Scientific Integrity
Research Misconduct
Related Article in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2006 98: 374-376.